Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a clinical-stage biopharmaceutical company focused on inflammatory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). Its news flow centers on the development of its lead antibody candidate, rademikibart, and on corporate and regulatory milestones that shape the company’s trajectory.
Readers following CNTB news can expect regular updates on clinical progress, including recruitment status and topline data timing for the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies, which evaluate rademikibart as an adjunct treatment for acute exacerbations. Company announcements also highlight new mechanism of action findings, post-hoc analyses of Phase 2b asthma data, and presentations at major medical meetings such as the European Respiratory Society Congress, the American Thoracic Society International Conference, and the European Academy of Allergy and Clinical Immunology Congress.
News items frequently cover regulatory and partnership developments, including the exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. in Greater China and the submission and acceptance of a New Drug Application for rademikibart for atopic dermatitis by China’s National Medical Products Administration. Investors also see coverage of capital markets actions, such as the termination of the company’s American Depositary Receipt program and the direct listing of its ordinary shares on the Nasdaq Global Market under the symbol CNTB.
Additional CNTB news includes financial results, board appointments, and community initiatives, such as the collaboration with the Jovante Woods Foundation to expand asthma education programs. For investors, analysts, and healthcare observers, this news page provides a centralized view of Connect Biopharma’s clinical, regulatory, financial, and outreach activities related to rademikibart and its broader inflammatory disease focus.
Connect Biopharma (CNTB) announced a revised timeline for its global Phase 3 program of CBP-201 in atopic dermatitis, now expected to start after securing partnerships. The cash runway is projected to extend into at least 2025, allowing ample time for ongoing trials and potential partnerships. The pivotal trial in China is on track, with Stage 2 completion expected in H2 2023. The company is also moving forward with CBP-307 in ulcerative colitis, with a Phase 2 maintenance phase expected to complete soon. Positive interactions with regulatory bodies are planned for early 2023.
Connect Biopharma (Nasdaq: CNTB) will present a corporate update led by CEO Zheng Wei, PhD, on January 9, 2023, at 9:00 am PST during the Biotech Showcase. The event takes place in San Francisco from January 9-11, 2023. Key executives, including CFO Steven Chan and CMO Chin Lee, will also be available for investor meetings. Connect Biopharma focuses on developing T cell-driven therapies for inflammatory diseases, with product candidates like CBP-201 for atopic dermatitis, CBP-307 for ulcerative colitis, and CBP-174 for pruritus.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) received a letter from Nasdaq on November 28, 2022, indicating that its American Depositary Shares (ADSs) have been below the minimum bid price of $1.00 for 30 consecutive business days. The company has until May 29, 2023, to regain compliance with Listing Rule 5550(a)(2). If compliance is not achieved, it may qualify for an additional 180-day period after transitioning to the Nasdaq Capital Market. The letter is a notification only and does not affect the trading of ADSs.
Connect Biopharma Holdings Limited (Nasdaq: CNTB), a biopharmaceutical firm focused on T cell-driven therapies for inflammatory diseases, announced its participation in several upcoming investor and scientific conferences. Key events include the 6th Annual Dermatology Drug Development Summit in Boston (Nov 1-3), where CEO Zheng Wei will present on Nov 2, and others through December, including the Piper Sandler Healthcare Conference in New York. The company continues to develop promising therapies, including its lead candidate targeting IL-4Rα for atopic dermatitis.
Summary not available.
Connect Biopharma (Nasdaq: CNTB) announced positive topline results from a pivotal trial of its lead candidate, CBP-201, for moderate-to-severe atopic dermatitis in 255 patients in China. The primary endpoint, achieving an IGA of 0 or 1 at Week 16, was met significantly (30.3% for CBP-201 vs. 7.5% placebo, p 0.001). Key secondary endpoints also showed significant efficacy. CBP-201 was well tolerated, with safety profiles similar to placebo. The company plans to advance discussions for a New Drug Application (NDA) in China.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will report topline results from its pivotal trial of lead candidate CBP-201 for moderate-to-severe atopic dermatitis (AD) in China. This highly anticipated announcement is set for tomorrow, October 4, 2022, and will be followed by a conference call and webcast at 5:30 a.m. PDT/8:30 a.m. EDT. The trial results will be significant for investors closely monitoring the company’s progress in treating inflammatory diseases.
Connect Biopharma (CNTB) announced key developments and financial results for the six months ending June 30, 2022. The company expects to report top-line data for its lead drug CBP-201 in atopic dermatitis in October 2022, ahead of schedule. They completed a global Phase 2b trial for CBP-201 showing positive efficacy, and R&D expenses rose to RMB 340.8 million due to ongoing clinical trials. The net loss was RMB 401.3 million, a decrease from the previous year's loss. The company has sufficient funds to support operations into at least 2024.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced it will report financial results for the six months ending June 30, 2022, on September 13, 2022, after market close. The company will host a webcast and conference call at 1:30 p.m. PDT to discuss these results along with a corporate update. Connect Biopharma focuses on developing therapeutics for T cell-driven inflammatory diseases, with key candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced the successful completion of its first-in-human Phase 1 study for CBP-174, an oral H3 receptor antagonist aimed at treating pruritus linked to allergic and inflammatory skin diseases, including atopic dermatitis. The trial demonstrated that CBP-174 was safe and well-tolerated with no serious adverse events reported. Vital signs and laboratory results showed no clinically notable safety findings. The Company aims to further evaluate CBP-174, intending to improve the quality of life for patients suffering from skin conditions worldwide.